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It is time to challenge the narrative 
that concern about overdiagnosis/
treatment and underdiagnosis/treatment 
are opposing world views. Passionate 
advocates on both sides of the debate battle 
for the hearts and minds of clinicians, 
policymakers, and the public. But this is a 
false dichotomy that inhibits us from finding 
solutions to important clinical dilemmas. 
Undertreatment and overtreatment are 
both examples of suboptimal care. They can 
coexist at population level and individual 
level, and they create real tensions for the 
clinician to balance. They both cause harm, 
both are difficult to get right, and both are 
aspects of primary care that would benefit 
from systematic quality improvement. Too 
often clinicians feel driven to support one 
polarised view or other. In reality, they 
need support to minimise under- and 
overtreatment, and to manage the tension 
between them.
How does this tension and suboptimal 
care manifest in day-to-day practice? There 
are many examples. Implementation of 
multiple single-condition guidelines in the 
individual patient can lead to pursuit of tight 
glycaemic or blood pressure control that 
does not take account of multimorbidity and 
individual risks and benefits.1 Treatment 
that is not tailored to the individual can 
lead to polypharmacy, reduced quality 
of life, and serious adverse effects. In 
people with known atrial fibrillation (AF) 
who suffer a stroke, 47% have not been 
anticoagulated before their stroke despite 
the overwhelming evidence of benefit.2 
There is wide variation among clinical 
commissioning groups (CCGs) (22% 
to 91%), suggesting that many of these 
strokes were preventable. In England, the 
average practice achieves blood pressure 
control to 150/90 in 79.6% of people with 
hypertension. But there is substantial 
variation: excluding outlying practices 
and including excepted patients in the 
denominator, achievement varies from 43% 
to 100%.3 In both stage 1 hypertension and 
raised 10-year cardiovascular risk, lifestyle 
modification is recommended as first-
line management. But, in practice, lack of 
time and resources to support behaviour 
change and shared decision making can 
shift the emphasis to medication. A recent 
study of secondary prevention before stroke 
analysed the general practice records of 
29 000 patients and found that, of 17 700 
patients for whom a specific preventive 
treatment was clinically indicated before 
their first stroke, 52% did not receive an 
anticoagulant, 25% did not receive an 
antihypertensive, and 49% did not receive 
a statin.4
In many cases, opting for treatment or 
non-treatment will reflect patient choice 
and wise professional judgement about 
what is in the patient’s best interest. But 
wide variation can suggest suboptimal care, 
with inappropriate or potentially harmful 
over- or undertreatment. This is what John 
Wennberg defines as the unwarranted 
variation that ‘cannot be explained on the 
basis of illness, medical evidence, or patient 
preference, but is accounted for by the 
willingness and ability of doctors to offer 
treatment’.5
Undertreatment and overtreatment 
matter to individual patients and 
populations. If anticoagulation rates for 
eligible people with AF increased from 74% 
to 89%, around 5000 additional strokes 
would be prevented over 5 years.6 If an 
individual has an avoidable stroke or 
heart attack because anticoagulation was 
not offered or high blood pressure was 
poorly managed, relatives would be right 
to question why evidence-based practice 
was not followed. If someone breaks a 
hip and loses their independence because 
over-aggressive blood pressure treatment 
caused them to fall, families would be 
justified in asking why treatment was not 
adapted to match the individual’s needs. 
WHY DOES UNDERTREATMENT AND 
OVERTREATMENT HAPPEN?
Iona Heath described overdiagnosis of the 
well and undertreatment of the sick as ‘the 
conjoined twins of modern medicine’.7 Both 
are examples of suboptimal care that are 
driven in part by structural barriers, system 
imperatives, and professional dilemmas 
that impact on front-line practice, but 
are largely beyond the reach of individual 
practitioners to resolve. For example, with 
current difficulties in recruitment, many 
GPs feel overwhelmed by workload and 
priorities: if we don’t have adequate staff 
or resources, if the systems and pathways 
to support us are not adequate, just doing 
our best will not guarantee optimal care. 
Consultations are high-pressure events 
where multiple priorities compete — 
apparently simple tasks like checking 
blood pressure or counselling about statins 
are not always feasible. Inflexible single-
condition guidelines and financial incentives 
can foster overtreatment, especially in those 
with multimorbidity. It is easier to prescribe 
than to have a complex consultation. In 
contrast, wide variation in use of exception 
reporting may mask undertreatment in 
some populations. Our biomedical training 
and lack of time and resources can make 
shared decision making and behaviour 
change support seem unrealistic. And, 
although most GPs do carry out some audit, 
we do not have comprehensive systems in 
place to identify which of our patients may 
be under- or overtreated. 
WHAT CAN WE DO ABOUT IT? 
If we are to reduce over- and 
undertreatment, this will not be achieved 
by asking GPs to work harder — there is 
no capacity for that. We will only achieve it 
by doing things differently, by changing the 
system to better support individual patients 
and clinicians.
First, clinical guidelines need to evolve. 
The National Institute for Health and 
Care Excellence has published guidance 
on the assessment and management 
of multimorbidity.8 The guidance 
recommends that treatments are tailored 
for the individual, with flexible guideline 
interpretation that is informed by patient 
values and preferences, balancing the 
relative benefits and risks of harm in 
order to prioritise what is safest and most 
effective for the individual. To help clinicians 
deliver optimal care to their patients, future 
guidelines should offer more than binary 
recommendations and simple targets. 
They should include resources that assist 
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“Undertreatment and overtreatment matter to 
individual patients and populations. ”
the clinician to interpret the complexities 
of benefit and harm, and to adapt the 
guidance to the individual patient. 
Second, the General Practice Forward 
View9 envisages significant care redesign 
arising from new models of general 
practice such as federations, super-
partnerships, and more integrated primary 
and community care. We should take this 
opportunity to adapt services and pathways 
to optimise management and reduce over- 
and undertreatment while minimising the 
burden on general practice. Examples 
could include commissioning pharmacists 
to support shared decision making and 
real patient choice for anticoagulants and 
statins; commissioning pharmacists to 
diagnose and manage hypertension, and to 
monitor anticoagulant control; integration 
into routine care of self-monitoring of blood 
pressure and warfarin; and more structured 
support for lifestyle modification outside 
general practice. Many of these innovations 
are already being implemented across the 
country, successfully optimising care for 
patients and supporting general practice 
(Williams H, personal communication; 
Arden C, personal communication; both 
February and March 2017).10 The NHS 
RightCare CVD prevention programme,11 
which is built on this approach, is now 
rolling out to all CCGs in England and 
brings an opportunity to do this at scale.
Third, proposals to adapt or replace the 
Quality and Outcomes Framework offer 
an opportunity to move from a box-ticking 
culture to a more mature approach to 
quality improvement. For example, 
should we consider reducing individual 
incentivised indicators and replacing them 
with a contractual requirement to take part 
in and act on systematic audit? This could 
be used to identify and address gaps in care 
(overtreatment and undertreatment) in key 
clinical areas, with local determination 
of priorities to be addressed. Such 
an approach would help strengthen 
professional accountability for quality 
improvement that is based on professional 
and patient definition of quality. And where 
we do retain incentivisation for processes of 
care, let’s reward shared decision making 
as well as prescribing.
PROFESSIONAL LEADERSHIP IS KEY
It is time to move on from polarised 
arguments which focus exclusively 
on overdiagnosis and treatment or 
underdiagnosis and treatment as the 
dominant problem. Both are key challenges 
for primary care, and GPs are favourably 
placed to take the lead in addressing 
both. Optimising individual care and 
managing the tensions between over- and 
undertreatment, and between individual 
benefit and benefit for our registered 
population, is difficult. But a core expertise 
of GPs is to balance competing priorities 
and to manage complexity, so we have a 
lot to offer in devising solutions. As general 
practice evolves with innovative ways of 
working, we should therefore take the 
professional lead. GPs and our professional 
bodies should develop a balanced 
consensus on these twin challenges and 
open a constructive debate on how to ensure 
optimal care for patients by reducing both 
overtreatment and undertreatment. And, in 
taking a leadership role, we can ensure that 
solutions reflect reality on the front line, 
and that they have transparency of evidence 
and shared decision making at their heart.
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